We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Seeding Assay May Boost Search for Huntington's Disease Drugs

By LabMedica International staff writers
Posted on 07 Jul 2015
An assay technique that measures seeding of mutant huntingtin aggregates in cerebral spinal fluid (CSF) may identify individuals with Huntington's disease (HD) that have not yet become symptomatic and may be used to evaluate the efficacy of new drug treatments for the disease.

Huntington’s disease is caused by a dominant gene that encodes a protein known as huntingtin (Htt). More...
The 5' end of the Huntington's disease gene has a sequence of three DNA bases, cytosine-adenine-guanine (CAG), coding for the amino acid glutamine, that is repeated multiple times. Normal persons have a CAG repeat count of between seven and 35 repeats, while the mutated form of the gene has anywhere from 36 to 180 repeats. The mutant form of Htt is broken down into toxic peptides, which contribute to the pathology of the syndrome.

Investigators at the University of California, Irvine (USA) reported in the June 23, 2015, online edition of the journal Molecular Psychiatry that synthetic polyglutamine oligomers and CSF from BACHD transgenic rats and from human HD subjects can seed mutant huntingtin aggregation in a cell model and its cell lysate.

Studies described in the paper demonstrated that seeding required the mutant huntingtin template and may have reflected an underlying prion-like protein propagation mechanism. Light and cryo-electron microscopy showed that synthetic seeds nucleated and enhanced mutant huntingtin aggregation. Seeding was dose dependent, and extracellular seeds were incorporated into endogenously expressed mutant Htt species, forming aggregated fibrils.

The seeding assay distinguished HD subjects from healthy and non-HD dementia controls without overlap. Ultimately, this seeding property in the CSF of HD patient may form the basis of a molecular biomarker assay to monitor HD and evaluate therapies that target mutant Htt.

"Determining if a treatment modifies the course of a neurodegenerative disease like Huntington's or Alzheimer's may take years of clinical observation," said senior author Dr. Steven Potkin, professor of psychiatry and human behavior at the University of California, Irvine. "This assay that reflects a pathological process can play a key role in more rapidly developing an effective treatment. Blocking the cell-to-cell seeding process itself may turn out to be an effective treatment strategy."

Related Links:

University of California, Irvine



Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Online QC Software
Acusera 24•7
Rapid Sepsis Test
SeptiCyte RAPID
New
Automated Urinalysis Solution
UN-9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.